Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients

Nephrology Dialysis Transplantation

Volumn 18, Issue 10, 2003, Pages 2147-2153

  Chanard, Jacques ^a   Toupance, Olivier ^a   Lavaud, Sylvie ^a   Hurault de Ligny, Bruno ^b   Bernaud, Corine ^c   Moulin, Bruno ^d  

^a HÔPITAL MAISON BLANCHE   (France)

^b CHU Clemenceau   (France)

^c PFIZER INC   (United States)

^d HÔPITAL CIVIL   (France)

Author keywords

Amlodipine; Calcium channel blockade; Cyclosporin A; Gout; Hyperuricaemia; Renal transplantation

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; SODIUM; TERTATOLOL; URIC ACID;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; KIDNEY PROXIMAL TUBULE; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ABSORPTION; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; URIC ACID BLOOD LEVEL;

ADULT; AMLODIPINE; CYCLOSPORINE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; HYPERTENSION; HYPERURICEMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROPANOLAMINES; REFERENCE VALUES; RISK ASSESSMENT; THIOPHENES; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0141507001     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg341     Document Type: Article

References (20)

1. Rodicio JL. Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients. J Cardiovasc Pharmacol 2000; 35 [Suppl 1]: S7-S11
2. Ruggenenti P, Perico N, Mosconi L et al. Calcium channel blockers protect transplant patients from cyclosporine induced daily renal hypoperfusion. Kidney Int 1993; 43: 706-711
3. Marcen R, Gallego N, Orofino L et al. Impairment of tubular secretion of urate in renal transplant patients on cyclosporine. Nephron 1995; 70: 307-313
4. Laine J, Holmberg C. Mechanisms of hyperuricemia in cyclosporine-treated renal transplanted children. Nephron 1996; 74: 318-323
5. Ruilope LM, Garcia-Puig J. Hyperuricemia and renal function. Curr Hypertens Rep 2001; 3: 197-202
6. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000; 11: 974-979
7. Hilbrands LB, Hoitsma AJ, Hamersvelt HW, Wetzels JFM, Huysmans F, Koene R. Acute effects of nifedipine in renal transplant recipients treated with cyclosporine or azathioprine. Am J Kidney Dis 1994; 24: 838-845
8. Toupance O, Lavaud S, Canivet E, Bernaud C, Hotton JM, Chanard J. Antihypertensive effect of amlodipine with cyclosporine metabolism in renal transplant patients. Hypertension 1994; 24: 297-300
9. Venkat-Raman G, Feehally J, Elliott HL et al. Renal and haemodynamic effects of amlodipine and nifedipine in hypertensive renal transplant recipients. Nephrol Dial Transplant 1998; 13: 2612-2616
10. Sennesael JJ, Lamote JG, Violet I, Tasse S, Verbeelen DL. Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients. Am J Kidney Dis 1996; 27: 701-708
11. Mazzali M, Kim Y-G, Suga S-I et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001; 71: 900-905
12. Rahn K-H, Barenbrock M, Fritschka E et al. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999; 354: 1415-1420
13. Branten AJ, Hilbrands LB, van Hamersvelt HW, Koene RA, Huysmans FT. Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A. Nephrol Dial Transplant 1998; 13: 423-426
14. Beaufils M. Alterations in renal hemodynamics during chronic and acute beta-blockade in humans. Am J Hypertens 1989; 11: 233S-236S
15. Krusell LR, Jespersen LT, Christensen CK, Thomsen K, Pedersen OL. Proximal tubular function in essential hypertensives on beta-blocker therapy with atenolol. Blood Press 1997; 6: 166-170
16. van der Schaaf MR, Hené RJ, Floor M, Blankestijn PJ, Koomans HA. Hypertension after renal transplantation: calcium channel or converting enzyme blockade. Hypertension 1995; 25: 77-81
17. Kamper A-L, Nielsen AH. Uricosuric effect of losartan in patients with renal transplants. Transplantation 2001; 72: 671-674
18. Inigo P, Campistol JM, Lario S et al. Effect of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001; 12: 822-827
19. Martinez AM, Heubi TR, Welch WF, Balisteri WF, Ryckman JC. Role of calcium channel blockers (amlodipine) in reversing cyclosporine or tacrolimus induced nephrotoxicity in pediatric orthotopic liver transplant (OLT) recipients. Gastroenterology 1996; 10 [Suppl 2]: 1259-1266
20. Venkat-Raman G, Feehally J, Coates RA et al. Renal effects of amlodipine in normotensive renal transplant patients. Nephrol Dial Transplant 1999; 14: 384-388